Study Maintenance Regorafenib vs Placebo, no Progression Patients After I Line Chemotherapy Metastatic Gastric Cancer

NCT ID: NCT03627728

Last Updated: 2025-03-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 67 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-06-13
• Study Completion Date: 2024-10-31

Brief Summary

Randomized, double-blind, placebo-controlled, multicenter Phase-II study.

Approximately 120 subjects with CR/PR/SD after platinum compounds and fluoropyrimidines based regimens: up to 6 cycles of cisplatin and 5-fluorouracil or capecitabine, up to 12 cycles of FOLFOX, up to 8 cycles of XELOX, will be randomly assigned (1:1 ratio) to one of the following treatment groups:

Arm A: Placebo 4 tablets once daily on day 1-21, every 4 weeks, until intolerance or progression disease Arm B: Regorafenib 160 mg, 4 tablets once daily on days 1-21, every 4 weeks, until intolerance or progression disease Primary Variable: PFS1

Conditions

Gastric Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

regorafenib

Regorafenib 160 mg, 4 tablets once daily on days 1-21, every 4 weeks, until intolerance or progression disease

Group Type: EXPERIMENTAL

Regorafenib

Intervention Type: DRUG

regorafenib/placebo

placebo

Placebo 4 tablets once daily on day 1-21, every 4 weeks, until intolerance or progression disease

Group Type: PLACEBO_COMPARATOR

placebo

Intervention Type: OTHER

regorafenib/placebo

Interventions

Regorafenib

regorafenib/placebo

Intervention Type: DRUG

placebo

regorafenib/placebo

Intervention Type: OTHER

Other Intervention Names

stivarga

Eligibility Criteria

Inclusion Criteria

1. Male of female ≥ 18 years of age

2. Have an Eastern Cooperative Oncology Group performance status of 0 or 1 within 14 days prior to the initiation of study treatment

3. Diagnosis of histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction

4. HER2 negative gastric or gastroesophagel junction cancer ( ICH 0, IHC 1+, IHC + FISH -)

5. Locally advanced/metastatic gastric or gastroesophageal junction cancer

6. CR/PR/SD after first-line platinum compound and Fluoropyrimidines based chemotherapy

7. Measurable disease according to RECIST 1.1 criteria

8. Have adequate bone marrow function, liver function, and renal function, as measured by the following laboratory assessments conducted within 7 days prior to the initiation of study treatment:

9. Total bilirubin 1.5 times the upper limit of normal (ULN)

10. Alanine aminotransferase and aspartate aminotransferase 3 times the ULN

11. Lipase 1.5 times the ULN

12. Serum creatinine 1.5 times the ULN

13. Glomerular filtration rate 30 mL/min/1,73 m2 according to the Modified Diet in Renal Disease abbreviated formula

14. International normalized ratio of prothrombin time and activated partial thromboplastin time 1.5 times the ULN. Subjects who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate if no underlying abnormality in coagulation parameters exists per medical history.

15. Platelet count 100,000 /mm3, hemoglobin 9 g/dL, absolute neutrophil count 1500/mm3 without transfusions or granulocyte colony stimulating factor and other hematopoietic growth factors

16. Alkaline phosphatase ≤ 2.5 times the ULN

17. Understand, be willing to give consent, and sign the written informed consent form (ICF) prior to undergoing any study-specific procedure.

18. If female and of childbearing potential, have a negative result on a pregnancy test performed a maximum of 7 days before initiation of study treatment.

19. If female and of childbearing potential, or if male, agree to use adequate contraception (eg, abstinence, intrauterine device, oral contraceptive, or double-barrier method) based on the judgment of the investigator or a designated associate from the date on which the ICF is signed until 8 weeks after the last dose of study drug.

8. Have had a major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to initiation of study treatment.

9. Are pregnant.

10. Are breastfeeding.

11. Are unable to swallow oral tablets (crushing of study treatment tablets is not allowed).

12. Have congestive heart failure classified as New York Heart Association Class 2 or higher

13. Have had unstable angina (angina symptoms at rest) or new-onset angina 3 months prior to screening.

14. Have had a myocardial infarction 6 months prior to initiation of study treatment.

15. Have cardiac arrhythmias requiring anti-arrhythmic therapy, with the exception of beta blockers or digoxin.

16. Have uncontrolled hypertension (systolic blood pressure [SBP] 140 mmHg or diastolic blood pressure [DBP] 90 mmHg) despite optimal medical management.

17. Have had arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within 6 months prior to the initiation of study treatment.

18. Have an ongoing infection with severity of Grade 2 or above (NCI-CTCAE v 4.0).

19. Have a known history of human immunodeficiency virus infection.

20. Have either active or chronic hepatitis B or C requiring treatment with antiviral therapy.

21. Have a seizure disorder requiring medication.

22. Have a history of organ allograft.

23. Have evidence or history of any bleeding diathesis (including mild hemophilia), irrespective of severity.

24. Have had a hemorrhage or a bleeding event Grade 3 (NCI-CTCAE v 4.0) within 4 weeks prior to the initiation of study treatment.

25. Have a nonhealing wound, ulcer, or bone fracture.

26. Have renal failure requiring hemodialysis or peritoneal dialysis.

27. Have dehydration Grade 1 (NCI-CTCAE v 4.0).

28. Have interstitial lung disease with ongoing signs and symptoms at the time informed consent is obtained.

29. Have persistent proteinuria > 3.5 g/24 hours measured by urine protein creatinine ratio from a random urine sample (Grade 3, NCI-CTCAE v 4.0).

30. Have any other serious or unstable illness, or medical, psychological, or social condition, that could jeopardize the safety of the subject and/or his/her compliance with study procedures, or may interfere with the subject's participation in the study or evaluation of the study results.

31. Have a known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation of the study drugs.

32. Have any malabsorption condition.

33. Have a close affiliation with the investigational site (eg, be a close relative of the investigator) or be a dependent person (eg, be an employee or student working at the investigational site).

34. Untreated gastro-esophageus varices

Exclusion Criteria

1. Are taking strong cytochrome P (CYP) CYP3A4 inhibitors (eg, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, voriconazole) or strong CYP3A4 inducers (eg, carbamazepine, phenobarbital, phenytoin, rifampin, St. John's Wort)

2. Have used biologic response modifiers, such as G-CSF, within 3 weeks of study entry

3. Have had prior treatment with regorafenib or any other VEGFR-targeting kinase inhibitor.

4. Completed their last dose of chemotherapy more than 8 weeks, whichever came later, prior to randomization.

5. Have had prior or concurrent cancer distinct in primary site or histology from GC or GJC within 5 years prior to randomization EXCEPT for curatively treated cervical cancer in situ, no-melanoma skin cancer, or superficial bladder tumors classified as noninvasive tumor (Ta), carcinoma in situ (Tis), or tumor invades lamina propria (T1).

6. Have had systemic anticancer therapy including cytotoxic therapy, signal transduction inhibitors, immunotherapy, and/or hormonal therapy within 4 weeks prior to initiation of study treatment.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Bayer

INDUSTRY

Sponsor Role: collaborator

Gruppo Oncologico Italiano di Ricerca Clinica

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Carmine Pinto, MD

Role: PRINCIPAL_INVESTIGATOR

Gruppo Oncologico Italiano di Ricerca Clinica

Locations

Struttura Complessa di OncologiaIRCCS- Istituto in Tecnologie Avanzate e Modelli Assistenziali in Oncologia Arcispedale Santa Maria Nuova

Reggio Emilia, , Italy

Countries

Italy

Other Identifiers

GOIRC-05-2016

Identifier Type: -

Identifier Source: org_study_id